JP2010507594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010507594A5 JP2010507594A5 JP2009533598A JP2009533598A JP2010507594A5 JP 2010507594 A5 JP2010507594 A5 JP 2010507594A5 JP 2009533598 A JP2009533598 A JP 2009533598A JP 2009533598 A JP2009533598 A JP 2009533598A JP 2010507594 A5 JP2010507594 A5 JP 2010507594A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85326006P | 2006-10-20 | 2006-10-20 | |
| PCT/US2007/082164 WO2008133706A2 (en) | 2006-10-20 | 2007-10-22 | Fully human anti-vegf antibodies and methods of using |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010507594A JP2010507594A (ja) | 2010-03-11 |
| JP2010507594A5 true JP2010507594A5 (OSRAM) | 2010-12-09 |
Family
ID=39926241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533598A Pending JP2010507594A (ja) | 2006-10-20 | 2007-10-22 | 完全ヒト抗ｖｅｇｆ抗体および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110076279A1 (OSRAM) |
| EP (1) | EP2086583A4 (OSRAM) |
| JP (1) | JP2010507594A (OSRAM) |
| CN (1) | CN102006885A (OSRAM) |
| CA (1) | CA2666974A1 (OSRAM) |
| MX (1) | MX2009004027A (OSRAM) |
| WO (1) | WO2008133706A2 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2066694T1 (sl) * | 2006-09-29 | 2016-02-29 | Oncomed Pharmaceuticals, Inc. | Sestavki in postopki za diagnosticiranje in zdravljenje raka |
| MX2010004327A (es) * | 2007-10-22 | 2010-05-13 | Schering Corp | Anticuerpos anti-vegf completamente humanos y metodos de uso. |
| KR101093717B1 (ko) * | 2008-11-26 | 2011-12-19 | 한국생명공학연구원 | Ｖｅｇｆ―특이적인 인간항체 |
| WO2010124009A2 (en) * | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CN102002104A (zh) * | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| TR201818814T4 (tr) | 2009-10-16 | 2019-01-21 | Oncomed Pharm Inc | Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı. |
| CN102167740B (zh) * | 2010-02-25 | 2014-06-04 | 上海百迈博制药有限公司 | 一种全人源抗vegf单克隆抗体、其制备方法及用途 |
| US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CN102757495A (zh) * | 2011-04-26 | 2012-10-31 | 中国人民解放军第二军医大学 | 一种全人源抗vegf抗体、其制备方法及用途 |
| CN102875676B (zh) * | 2011-07-13 | 2014-11-05 | 无锡天演生物技术有限公司 | 全人源抗人vegf单抗分子及其应用 |
| PT3485903T (pt) | 2011-09-23 | 2023-02-17 | Mereo Biopharma 5 Inc | Agentes de ligação a vegf/dll4 e utilizações dos mesmos |
| CA2889638A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| WO2014104406A1 (ja) * | 2012-12-27 | 2014-07-03 | 学校法人慶應義塾 | 骨粗鬆症治療剤及び治療剤のスクリーニング方法 |
| KR20150132581A (ko) * | 2013-12-31 | 2015-11-25 | 재단법인 생물기술개발중심 | 항-vegf 항체 및 그것의 용도 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2808153T3 (es) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| US10640772B2 (en) | 2015-11-30 | 2020-05-05 | Nissan Chemical Industries, Ltd. | DNA aptamers binding to molecular targeted agents and detection method of molecular targeted medicine using the same |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| AU2017315076B2 (en) | 2016-08-23 | 2020-10-08 | Medimmune Limited | Anti-VEGF-A antibodies and uses thereof |
| EP3731865A1 (en) | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche AG | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN113272323A (zh) * | 2018-12-21 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 用于改善抗vegf抗体对vegf与vegf-r1的结合的抑制的方法 |
| CN114174335B (zh) * | 2019-07-19 | 2023-12-15 | 神州细胞工程有限公司 | 一种人源化vegfr2抗体及其应用 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2023109904A1 (zh) * | 2021-12-16 | 2023-06-22 | 石药集团中奇制药技术（石家庄）有限公司 | 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及用途 |
| EP4499709A2 (en) * | 2022-03-30 | 2025-02-05 | Xi An Orimab Biotechnology Company Ltd. | Anti-psma antibodies, variants, and uses thereof |
| CN115850470B (zh) * | 2022-12-12 | 2023-07-07 | 三门峡市眼科医院 | Vegf抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2273415T3 (es) * | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| KR100857943B1 (ko) * | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| EP1439192A1 (en) * | 2003-01-15 | 2004-07-21 | Xerion Pharmaceuticals AG | Neuropilin-1 inhibitors |
| ES2453973T3 (es) * | 2005-02-02 | 2014-04-09 | University Of Massachusetts | Anticuerpos humanos contra la rabia y usos de los mismos |
| MX2010004327A (es) * | 2007-10-22 | 2010-05-13 | Schering Corp | Anticuerpos anti-vegf completamente humanos y metodos de uso. |
-
2007
- 2007-10-22 CA CA002666974A patent/CA2666974A1/en not_active Abandoned
- 2007-10-22 JP JP2009533598A patent/JP2010507594A/ja active Pending
- 2007-10-22 WO PCT/US2007/082164 patent/WO2008133706A2/en not_active Ceased
- 2007-10-22 MX MX2009004027A patent/MX2009004027A/es unknown
- 2007-10-22 CN CN2007800475418A patent/CN102006885A/zh active Pending
- 2007-10-22 EP EP07874227A patent/EP2086583A4/en not_active Withdrawn
- 2007-10-22 US US12/446,438 patent/US20110076279A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010507594A5 (OSRAM) | ||
| HRP20200241T1 (hr) | Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti | |
| JP2011207882A5 (OSRAM) | ||
| JP2017523786A5 (OSRAM) | ||
| JP2016519650A5 (OSRAM) | ||
| JP2011518546A5 (OSRAM) | ||
| JP2009225799A5 (OSRAM) | ||
| JP2017505125A5 (OSRAM) | ||
| JP2015535828A5 (OSRAM) | ||
| JP2017514461A5 (OSRAM) | ||
| JP2008529497A5 (OSRAM) | ||
| JP2020504076A5 (OSRAM) | ||
| JP2014509510A5 (OSRAM) | ||
| JP2009518005A5 (OSRAM) | ||
| HRP20130228T1 (hr) | Antitijela s visokim afinitetom za receptor humanog il 6 | |
| JP2015504421A5 (OSRAM) | ||
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| JP2014530215A5 (OSRAM) | ||
| JP2012524071A5 (OSRAM) | ||
| JP2015514110A5 (OSRAM) | ||
| JP2014500009A5 (OSRAM) | ||
| JP2010538608A5 (OSRAM) | ||
| JP2019504032A5 (OSRAM) | ||
| JP2017500018A5 (OSRAM) | ||
| JP2016507470A5 (OSRAM) |